Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Ceritinib following crizotinib relapse for ALK positive NSCLC

Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016

Significant survival gains with atezolizumab for NSCLC

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016

KRAS in the clinic and conference

Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
9 Oct 2016

A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

Dr Arndt Stahler - University of Munich, Munich, Germany
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1) ( Dr Arndt Stahler - University of Munich, Munich, Germany )
9 Oct 2016

Phase I results of a novel FGFR inhibitor

Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland
Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )
9 Oct 2016

Firstline pembrolizumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
9 Oct 2016

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer

Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France
Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer ( Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France )
8 Oct 2016

Ribociclib improves progression-free survival in advanced breast cancer

Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US
Ribociclib improves progression-free survival in advanced breast cancer ( Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US )
8 Oct 2016

Niraparib significantly improves outcomes for ovarian cancer patients

Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark
Niraparib significantly improves outcomes for ovarian cancer patients ( Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark )
8 Oct 2016

Ipilimumab as adjuvant therapy improves OS in high risk melanoma

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France
Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )
8 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation